Valeo Pharma Inc.
VPHIF
$0.0469
-$0.0471-50.11%
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.38% | 19.52% | 44.96% | 87.30% | 174.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.38% | 19.52% | 44.96% | 87.30% | 174.38% |
| Cost of Revenue | 7.80% | 33.73% | 57.90% | 103.91% | 201.57% |
| Gross Profit | -26.35% | -16.14% | 12.89% | 49.98% | 120.30% |
| SG&A Expenses | -10.80% | 0.13% | 3.96% | 6.40% | 7.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.07% | 18.18% | 30.61% | 47.94% | 71.35% |
| Operating Income | -4.84% | -14.14% | 1.85% | 15.11% | 28.74% |
| Income Before Tax | -9.05% | -2.56% | -1.60% | 0.89% | -14.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.68% | -6.95% | -6.12% | -3.50% | -9.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.68% | -6.95% | -6.12% | -3.50% | -9.40% |
| EBIT | -4.84% | -14.14% | 1.85% | 15.11% | 28.74% |
| EBITDA | -4.09% | -11.73% | 8.17% | 24.00% | 36.64% |
| EPS Basic | 0.08% | 3.35% | 0.99% | 2.64% | -5.59% |
| Normalized Basic EPS | 8.21% | 2.68% | 2.69% | 4.44% | -4.83% |
| EPS Diluted | 0.08% | 3.35% | 0.99% | 2.64% | -5.59% |
| Normalized Diluted EPS | 8.21% | 2.68% | 2.69% | 4.44% | -4.83% |
| Average Basic Shares Outstanding | 13.68% | 10.30% | 6.75% | 5.83% | 3.49% |
| Average Diluted Shares Outstanding | 13.68% | 10.30% | 6.75% | 5.83% | 3.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
